

SUBSCRIPTION FORM FOR SUBSCRIPTION OF SHARES WITHOUT SUBSCRIPTION RIGHTS IN STAYBLE THERAPEUTICS AB

Subscription period:	3 February – 17 February 2021
Subscription price per share:	SEK 6.00
Allocation:	Any allotment will be notified via a settlement note via e-mail
Payment:	To be made in accordance with instructions on the settlement note.

PLEASE NOTE

Subscribers who have a custody account or account with specific rules, such as an ISK/KF account, the subscription must be made in agreement with the bank/trustee that holds the account.

In an assessment of Stayble Therapeutics AB future development and operations, it is of great importance to consider all relevant risks. Each investor must make their own assessment of the impact of these risks by reading and understanding all available information published concerning this offer. The prospectus is available for download at www.sedermera.se, www.nordic-issuing.se and at www.staybletherapeutics.com.

1. The undersigned hereby applies for subscription of the following number of shares in Stayble Therapeutics AB at a subscription price of SEK 6.00 per share:

Number of shares

2. Fill in where the allotted and paid for shares (BTA) are to be delivered, VP-/Service account or custody account (state only one alternative):

VP-/Service account OOO	Bank/Trustee
Custody account	Bank/ Trustee

3. The undersigned claims preferential right in the event that the offer is oversubscribed. In the event that the offer is oversubscribed, priority in allocation of shares subscribed for without subscription rights will be given to investors who have also subscribed for shares with subscription rights in the rights issue, in relation to the number of subscription rights being exercised. Invoke this preferential right by filling in the number of shares you have subscribed for with subscription rights in this rights issue, and indicate the bank/trustee via which such subscription was made:

Number of shares	Bank/Trustee	VP-/Service account/Custody account
------------------	--------------	-------------------------------------

4. How many times have You invested through Nordic Issuing the last two (2) years?

0-9 ☐ 10 or more ☐

5. Subscription over 15 000 EURO or answering "10 or more" to question 4 above?

If the subscription amounts to or exceeds 15 000 EURO, or if the answer to question 4 is "10 or more" a money laundering form which can be found at Nordic Issuings website shall be filled out and signed with BankID or NemID. Please note: Nordic Issuing cannot guarantee that the subscription form will be considered if Nordic Issuing does not receive a completed money laundering form before the subscription period has ended.

6. Fill in your name and address information (PLEASE WRITE CLEARLY)

Last name/company name		First name		National ID number/Corp.ID.no.	
Street address (or PO Box or equivalent)			Daytime telephone		NID-number (private person)*/LEI (company)**
Postal code	City	Country (if other than Sweden)		E-mail (mandatory!)	
Place and date			Signature (authorized company signature, or guardian, if applicable)		

* **NID** is a national ID for physical persons, required when subscribing for, trading, buying, selling and moving securities. Please fill in if you have dual citizenship or citizenship outside Sweden and Denmark.

** **LEI** is a global ID-code for legal persons, required when subscribing for, trading, buying, selling and moving securities. Application for LEI-code can be made with support from your bank, but is also possible to conduct directly through companies providing LEI-codes.

7. By signing this subscription form I confirm the following:

- ☐ That I have read the prospectus (Swedish use) and understood the risks associated with investing in this particular financial instrument;
- ☐ That I have read and understood the information stated in the section "terms for the offer" in the prospectus;
- ☐ That I have read and accepted the information stated on the subscription form;
- ☐ That no modifications or amendments may be made to the printed text in this subscription form;
- ☐ That an incomplete or incorrect subscription form may be disregarded;
- ☐ That I am aware that no customer relationship exists between Nordic Issuing and the subscriber with respect to this subscription;
- ☐ That I am aware that Nordic Issuing will not make any assessment of whether the subscription to the instrument in question is suitable for me or the person on whose behalf I am subscribing;
- ☐ I have observed that the offer is not addressed to persons resident in the USA, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore or other countries where participation requires additional prospectus, registration or other measures other than those required by Swedish law;
- ☐ That I am aware that the application is not covered by the right of return that follows from the Swedish Distant and Doorstep Sales Act;
- ☐ That the subscription is binding;
- ☐ That in signing this subscription form, I authorize Nordic Issuing, at the undersigned's expense, to implement the subscription of shares pursuant to the terms and conditions stated in the prospectus issued by the board of directors of Stayble Therapeutics AB in January 2021;
- ☐ That personal data will be stored and processed in accordance with the General Data Protection Regulation (GDPR);
- ☐ That I am aware that I am only allowed to submit one subscription form per signatory. In case several subscription forms are submitted, only the last received will be considered;
- ☐ That the allocation of shares in accordance with the subscription cannot be guaranteed.

☐ By checking this box, the subscriber agrees that information provided on the subscription form may also be used for communication regarding offers in the future.

8. Send the application form by one of the following options:

Mail:
Subject: Stayble Therapeutics AB
Nordic Issuing
Norra Vallgatan 64
211 22 Malmö

E-mail:
info@nordic-issuing.se
Web site: www.nordic-issuing.se

Other questions:
Phone: 0046 40-632 00 20